Research Topics
| G JankaSummaryAffiliation: University of Hamburg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Modern management of children with haemophagocytic lymphohistiocytosisGritta E Janka
Department of Haematology and Oncology, Children's Hospital, University of Hamburg, Hamburg, Germany
Br J Haematol 124:4-14. 2004
[In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-0G E Janka-Schaub
Abt für Pädiatrische Hämatologie und Onkologie, Universitätskinderklinik Hamburg
Klin Padiatr 211:233-8. 1999..Additional prognostic criteria are therefore urgently needed. In a retrospective Dutch study in childhood ALL drug sensitivity testing with the MTT assay was identified as a new highly significant prognostic factor...
Hemophagocytic lymphohistiocytosis: when the immune system runs amokG Janka
Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Klin Padiatr 221:278-85. 2009..Suppression of the severe hyperinflammation can be achieved with immunosuppressive and immunomodulatory agents and cytostatic drugs. Patients with genetic HLH have to undergo stem cell transplantation for cure...
Familial and acquired hemophagocytic lymphohistiocytosisG E Janka
Department of Hematology and Oncology, Children s University Hospital, Hamburg, Germany
Annu Rev Med 63:233-46. 2012..Treatment of HLH includes immune-suppressive and immune-modulatory agents, cytostatic drugs, and biological response modifiers. For patients with FHL, stem cell transplantation is indicated and can be curative...
Hemophagocytic syndromesGritta E Janka
Department of Hematology and Oncology, Children s Hospital, University of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
Blood Rev 21:245-53. 2007..Awareness of the clinical symptoms and of the diagnostic criteria of HLH is important to start life-saving therapy with immunosuppressive/immunomodulatory agents in time...
Familial and acquired hemophagocytic lymphohistiocytosisGritta E Janka
Department of Hematology and Oncology, Children s Hospital, University of Hamburg, Hamburg, Germany
Eur J Pediatr 166:95-109. 2007..In conclusion, awareness of the clinical symptoms and of the diagnostic criteria of HLH is crucial in order not to overlook HLH and to start life-saving therapy in time...
[Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]U zur Stadt
Abt für Pädiatrische Hämatologie und Onkologie, Universitätskinderklinik Eppendorf, Hamburg
Klin Padiatr 212:169-73. 2000..At the end of induction therapy, bone marrow was obtained for cytomorphologic and molecular analysis...
From neonates to adolescents--the diagnostic significance of pitted erythrocytes in hyposplenic and asplenic childrenK Lehmberg
Department of Paediatric Haematology and Oncology, Children s Hospital, University of Hamburg, Hamburg
Klin Padiatr 219:339-42. 2007..A simple method with reliable reference values is required to determine a patient's splenic function and thereby assess the risk of systemic infection...
Distribution of cardiac iron measured by magnetic resonance imaging (MRI)-R*2Jin Yamamura
University Medical Center Hamburg Eppendorf, Hamburg, Germany
J Magn Reson Imaging 32:1104-9. 2010..To assess regional iron distribution by magnetic resonance imaging (MRI)-R(2)* within the heart of patients with β-thalassemia major (TM) and other iron overload diseases...
Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemiaUlrike B Graubner
University Children s Hospital, Department of Hematology and Oncology, Munich, Germany
Pediatr Blood Cancer 50:259-63. 2008..Infections are a major cause of morbidity and mortality in childhood acute lymphoblastic leukemia (ALL) and only limited information is available on infectious complications...
